Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment

Author:

Hayden Frederick G1,Asher Jason2,Cowling Benjamin J3,Hurt Aeron C4,Ikematsu Hideyuki5,Kuhlbusch Klaus4,Lemenuel-Diot Annabelle4,Du Zhanwei3,Meyers Lauren Ancel6,Piedra Pedro A7,Takazono Takahiro8,Yen Hui-Ling3,Monto Arnold S9

Affiliation:

1. Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA

2. Leidos, Reston, Virginia, USA

3. School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China

4. F. Hoffmann-La Roche Ltd., Basel, Switzerland

5. Ricerca Clinica, Fukuoka, Japan

6. Departments of Integrative Biology and Statistics & Data Sciences, University of Texas, Austin, Texas, USA

7. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA

8. Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

9. University of Michigan School of Public Health, Ann Arbor, Michigan, USA

Abstract

Abstract Prompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication after antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients seems to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modeling studies indicate that early treatment could have major epidemiologic benefits in seasonal and pandemic influenza.

Funder

F. Hoffmann-La Roche Ltd.

University of Hong Kong

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference44 articles.

1. Influenza virus;Hayden,2017

2. Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings—personal protective and environmental measures;Xiao;Emerg Infect Dis,2020

3. Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings—social distancing measures;Fong;Emerg Infect Dis,2020

4. Respiratory virus shedding in exhaled breath and efficacy of face masks;Leung;Nat Med,2020

5. Which influenza viruses will emerge following the SARS-CoV-2 pandemic?;Laurie;Influenza Other Respir Viruses

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3